The Putative Effects of Neoadjuvant Chemotherapy on the Immune System of Advanced Epithelial Ovarian Carcinoma

被引：1

作者：

Li, Yunyun ^{[1
,2
]}

Gan, Xiaoling ^{[2
]}

Li, Fei ^{[1
]}

Hu, Lina ^{[2
,3
]}

机构：

[1] Chongqing Med Univ, Dept Gynecol & Obstet, Yongchuan Hosp, Chongqing, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 2, Dept Gynecol, Chongqing, Peoples R China

[3] Chongqing Med Univ, Dept Gynecol & Obstet, Affiliated Hosp 2, 288 Tianwen Rd, Chongqing, Peoples R China

来源：

IMMUNOLOGICAL INVESTIGATIONS | 2024年 / 53卷 / 02期

关键词：

Epithelial ovarian cancer (EOC); immune reactive; immune suppressive; interval debulking surgery (IDS); neoadjuvant chemotherapy (NACT); tumor immune microenvironment (TME); REGULATORY T-CELLS; DENDRITIC CELLS; CANCER; TRIAL; MICROENVIRONMENT; RECURRENCE; TOLERANCE; FREQUENCY; SURGERY;

D O I：

10.1080/08820139.2023.2284885

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The epithelial ovarian carcinoma (EOC) is one of leading causes of cancer-related mortality in females. For some patients, complete resection cannot be achieved, thus neoadjuvant chemotherapy (NACT) following interval debulking surgery (IDS) could be an alternative choice. In general-held belief, cytotoxic chemotherapy is assumed to be immunosuppressive, because of its toxicity to dividing cells in the bone marrow and peripheral lymphoid tissues. However, increasing evidence highlighted that the anticancer activity of chemotherapy may also be related to its ability to act as an immune modulator. NACT not only changed the morphology of cancer cells, but also changed the transcriptomic and genomic profile of EOC, induced proliferation of cancer stem-like cells, gene mutation, and tumor-related adaptive immune response. This review will provide a comprehensive overview of recent studies evaluating the impact of NACT on cancer cells and immune system of advanced EOC and their relationship to clinical outcome. This information could help us understand the change of immune system during NACT, which might provide new strategies in future investigation of immuno-therapy for maintenance treatment of EOC.

引用

页码：91 / 114

页数：24

共 70 条

[51] Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression [J].

Napoletano, Chiara ;

Bellati, Filippo ;

Landi, Rachele ;

Pauselli, Simona ;

Marchetti, Claudia ;

Visconti, Valeria ;

Sale, Patrizio ;

Liberati, Marco ;

Rughetti, Aurelia ;

Frati, Luigi ;

Panici, Pierluigi Benedetti ;

Nuti, Marianna .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (12) :2748-2759

[52] Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer [J].

Parkes, Eileen E. ;

Walker, Steven M. ;

Taggart, Laura E. ;

McCabe, Nuala ;

Knight, Laura A. ;

Wilkinson, Richard ;

McCloskey, Karen D. ;

Buckley, Niamh E. ;

Savage, Kienan I. ;

Salto-Tellez, Manuel ;

McQuaid, Stephen ;

Harte, Mary T. ;

Mullan, Paul B. ;

Harkin, D. Paul ;

Kennedy, Richard D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (01)

[53] The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry [J].

Pavlidis, Nicholas ;

Rassy, Elie ;

Vermorken, Jan B. ;

Assi, Tarek ;

Kattan, Joseph ;

Boussios, Stergios ;

Smith-Gagen, Julie .

CANCER EPIDEMIOLOGY, 2021, 75

[54] B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape [J].

Pesce, Silvia ;

Tabellini, Giovanna ;

Cantoni, Claudia ;

Patrizi, Ornella ;

Coltrini, Daniela ;

Rampinelli, Fabio ;

Matta, Jessica ;

Vivier, Eric ;

Moretta, Alessandro ;

Parolini, Silvia ;

Marcenaro, Emanuela .

ONCOIMMUNOLOGY, 2015, 4 (04)

[55] Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma [J].

Poelcher, Martin ;

Braun, Michael ;

Friedrichs, Nicolaus ;

Rudlowski, Christian ;

Bercht, Eva ;

Fimmers, Rolf ;

Sauerwald, Axel ;

Keyver-Paik, Mignon-Denise ;

Kuebler, Kirsten ;

Buettner, Reinhard ;

Kuhn, Walther C. ;

Hernando, Juan-Jose .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (06) :909-919

[56] BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery [J].

Ponzone, Riccardo .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157

[57] A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients [J].

Rahma, Osama E. ;

Ashtar, Ed ;

Czystowska, Malgorzata ;

Szajnik, Marta E. ;

Wieckowski, Eva ;

Bernstein, Sarah ;

Herrin, Vincent E. ;

Shams, Mortada A. ;

Steinberg, Seth M. ;

Merino, Maria ;

Gooding, William ;

Visus, Carmen ;

DeLeo, Albert B. ;

Wolf, Judith K. ;

Bell, Jeffrey G. ;

Berzofsky, Jay A. ;

Whiteside, Theresa L. ;

Khleif, Samir N. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (03) :373-384

[58] Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer [J].

Revythis, Antonios ;

Limbu, Anu ;

Mikropoulos, Christos ;

Ghose, Aruni ;

Sanchez, Elisabet ;

Sheriff, Matin ;

Boussios, Stergios .

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (14)

[59] Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes [J].

Shah, Sidrah ;

Cheung, Alison ;

Kutka, Mikolaj ;

Sheriff, Matin ;

Boussios, Stergios .

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (13)

[60] The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma [J].

Shen, Yuanming ;

Ren, Yan ;

Chen, Kelie ;

Cen, Yixuan ;

Zhang, Bo ;

Lu, Weiguo ;

Xu, Junfen .

ONCOGENESIS, 2022, 11 (01)

← 1 2 3 4 5 6 7 →